In a stunning turn for its oncology drug, rociletinib (CO-1686), Clovis Oncology Inc. reported that the FDA wants additional clinical data to evaluate the efficacy of the 500 mg and 625 mg dose groups in the treatment of NSCLC patients with initial activating epidermal growth factor receptor mutations, as well as the dominant resistance mutation T790M.